Navigation Links
A New, Objective Way to Assess Visual Fields: Visual Evoked Potentials
Date:8/2/2011

PINE BROOK, N.J., Aug. 2, 2011 /PRNewswire/ -- A new visual evoked potential method has been developed to objectively assess visual field defects in patients with ocular and/or neurological conditions. The research team of Kenneth Ciuffreda, OD, PhD, Diana Ludlam and Naveen Yadav at the SUNY State College of Optometry, Department of Vision Sciences (New York, NY) presented a scientific poster called "Effect of Different Stimulus Configurations on the Visually Evoked Potential (VEP)" at the 2011 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The purpose of the study was to assess the effect of different stimuli on VEP results, with the future goal of using the method as an objective form of visual field testing.

Traditionally, visual field tests consist of a patient looking into the center of a concave dome and pressing a button when they see a flash of light. This is meant to help map the patient's peripheral and central vision. However, the visual field test is a subjective exam because it requires the patient to understand the test instructions and fully cooperate to obtain accurate results. The process may be difficult and time consuming for some patients, often leading to poor repeatability and reliability. It is especially difficult for special patient populations such as those with cognitive impairments or attention deficits like Alzheimer's, ADHD, and acquired brain injury (ABI). Dr. Ciuffreda, a Distinguished Teaching Professor at SUNY and an optometrist says, "I rarely rely on the first visual field test I give a patient. I need to see the results repeated at least once to make sure that the patient fully understood what they were supposed to do, and that they were paying attention during the entire duration of the test."

The new VEP method overcomes many of the downfalls of traditional visual field testing. The device, called the Diopsys® NOVA VEP Vision Testing System, is an objective, rapid, repeatable and non-invasive method to quantify the integrity and functionality of the retina and visual pathway.  Patients simply watch a monitor that uses a black and white pattern that appears to "flip" back and forth to stimulate the vision system. Patients do not have to verbally respond nor press any buttons, which helps the doctor to be more confident in the results. Testing may take as little as five minutes, and results may be used to correlate with other conventional vision tests.

"This VEP technique also shows promise for assessing and documenting the visual status of troops pre- and post deployment. Bomb blasts from IED's frequently cause injuries to the brain resulting in mild to severe cognitive impairment. These impairments often preclude the use of other testing methods as poor patient response renders certain tests ineffectual," says Dr. Ciuffreda.

VEP vision testing covers a wide range of visual and neurological conditions such as glaucoma, macular degeneration, Alzheimer's disease, and visual problems associated with stroke and traumatic brain injury (TBI). The results of this study will be used to develop specific protocols for objectively assessing residual visual field functionality in ocular and neurological conditions, as well as the disorders already mentioned.

Diopsys, Inc. (http://www.diopsys.com) is a medical instrumentation company dedicated to delivering high quality, cost-effective preventative health care solutions. The company specializes in the development and marketing of patient-friendly, non-invasive vision testing equipment utilizing Visual Evoked Potential.

Diopsys developed and markets the patented Enfant® Pediatric VEP Vision Testing System, a device used by pediatricians to test for visual deficits, including amblyopia, in children as young as six months. Diopsys also provides the Diopsys® NOVA-VEP Vision Testing Systems utilized by eye care professionals to aid in the detection, diagnosis and treatment of vision disorders.


'/>"/>
SOURCE Diopsys, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kinetics Foundation and National Parkinson Foundation (NPF) Announce their Partnership to Evaluate Objective Parkinsons Disease Measurement System
2. Amgen Outlines Strategy, Growth Objectives and Capital Allocation Plans
3. PNP Therapeutics Meets Important Financial and Regulatory Objectives in Development of New Cancer Therapies
4. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
5. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
6. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
7. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
8. Rcadias Fully Automatic Calcium Score Assessment from Coronary CTA Shows Potential to Eliminate Need for Separate Scan
9. DaTscan™ (Ioflupane I 123 Injection) Now Available to Help Physicians Assess Patients with Suspected Parkinsonian Syndromes
10. Auxogyn Announces Issuance of Key Patent Covering Predictive Embryo Assessment Parameters for In Vitro Fertilization
11. Reportlinker Adds Global CRO Market: Quantitative Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Actinic Keratosis Market ... to their offering.       (Logo: ... Keratosis Market and Competitive Landscape Highlights 2016, ... products, Actinic Keratosis epidemiology, Actinic Keratosis market ...
(Date:5/3/2016)... Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and increase market presence. ... ... ... ... Sino-German High-Tech Fund ...
(Date:5/3/2016)... Ore. , May 3, 2016   BIOTRONIK ... importance of extending care beyond the implant at the ... May 4-7 in San Francisco . ... continually delivering the highest quality of patient care and ... are cared for each and every tomorrow," said ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... The RIDER ... and development of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against all ... May 3, 2016 at http://igg.me/at/EndTheVirus and runs for 60 days, we ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... Nike Rugby ... junior rugby in San Diego. Willis, founder of Elite Rugby Camps and current Nike ... and players every year since 2009. , “I’m excited for our eighth summer ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... a master charity program created to assist the people of their local community. ... with nonprofit organizations and community leaders. Their hope is to bring awareness to ...
(Date:5/4/2016)... ... May 04, 2016 , ... Dr. Elyson and Dr. Assili, ... surgery at their office. Wisdom tooth removal, a common dental procedure, is performed for ... often are improperly erupted, resulting in risks of complications. By providing wisdom tooth removal ...
(Date:5/4/2016)... ... ... Francesca Loparco, Co-Founder of Queen City Dream Cars, an exotic car rental business ... at Christenbury Eye Center. The entrepreneur struggled with her computer, riding horses and driving ... her in-office consultation and eye exam. Francesca’s eyesight was restored to 20/20 in both ...
Breaking Medicine News(10 mins):